| Dr John F Derossi, MD | |
|
18 Marion House Dr, Bolton Landing, NY 12814 | |
| (518) 668-9080 | |
| (518) 668-2705 |
| Full Name | Dr John F Derossi |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 18 Marion House Dr, Bolton Landing, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326341975 | NPI | - | NPPES |
| AD8333611 | Other | NY | BNDD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 135664-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John F Derossi, MD Box 315, 18 Marion House Dr, Bolton Landing, NY 12814 Ph: (518) 668-9080 | Dr John F Derossi, MD 18 Marion House Dr, Bolton Landing, NY 12814 Ph: (518) 668-9080 |
News Archive
Life Sciences Minister George Freeman today (16 December) announced £10 million investment in five new research centres around the UK that will explore how mathematics and statistics can help clinicians to tackle serious health challenges such as cancer, heart disease and antibiotic resistant bacteria.
Like the plastic caps at the end of shoelaces, telomeres protect — in their case — the interior-gene containing parts of chromosomes that carry a cell's instructional material. Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by Johns Hopkins scientists.
New figures to be presented at a Royal College of Physicians (RCP) conference today will show that every week in the UK one hospitality industry employee dies from passive smoking at work. The new figures, calculated by Professor Konrad Jamrozik of Imperial College in London, will be presented at the RCP conference called ‘Environmental Tobacco Smoke and the Hospitality Industry'.
Patients and healthcare providers at the Princess Margaret Cancer Centre rated virtual care during COVID-19 as highly satisfactory overall for quality of care and convenience, while at the same time saving patients millions in costs.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
› Verified 6 days ago